Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model
PubMed 42542926 · doi:10.52312/jdrs.2026.2951
What was done
Thirty-two male Sprague-Dawley rats underwent standardized Achilles tendon transection with surgical repair and were randomized into four groups of eight: control, intraperitoneal BPC-157 (10 µg/kg/day), intraperitoneal TB-500 (synthetic thymosin beta-4, 60 µg/kg/day), or combined BPC-157 plus TB-500 for four weeks. At four weeks postoperatively, harvested tendons were evaluated for maximum load to failure via biomechanical testing, structural recovery via Bonar and Movin histopathological scoring (using hematoxylin-eosin, Masson trichrome, Alcian blue, and Sirius red staining), and collagen type I and III expression via immunohistochemical H-score analysis.
What was found
Biomechanical testing demonstrated higher maximum load to failure in both peptide monotherapy groups compared to controls, reaching statistical significance only for TB-500 (p < 0.05). Histopathologically, TB-500 significantly reduced total Bonar scores (p = 0.016) and total Movin scores (p = 0.017), while the combination group also significantly reduced Movin scores (p = 0.040) relative to controls; BPC-157 alone showed numerical reductions that did not reach statistical significance. Sirius red birefringence showed enhanced type I collagen organization, particularly with TB-500. Immunohistochemistry revealed no significant difference in collagen type I expression across groups, but collagen type III expression differed significantly. Combined treatment provided no additive benefits compared to single agents. Exact numeric values (means, standard deviations, or load measurements) were not reported in the abstract.
Why it matters
This study provides direct preclinical comparative evidence on the popular experimental peptides BPC-157 and TB-500, indicating that TB-500 confers superior structural and biomechanical tendon healing benefits over BPC-157 at the tested doses, while demonstrating no synergy from their concurrent use.
Limits
Findings are limited to a small animal model (n = 8 per group) with a short follow-up duration of four weeks, precluding long-term remodeling assessment and direct translation to humans. Only a single dosage of each peptide was tested without dose-optimization, and the abstract omits raw biomechanical values, baseline metrics, and exact collagen quantification data.
Cited by
- supports TB-500 promotes blood flow and tissue repair at injury sites.